B. Riley Has Optimistic Outlook of Vaxart FY2024 Earnings

Vaxart, Inc. (NASDAQ:VXRT - Free Report) - Equities research analysts at B. Riley raised their FY2024 earnings per share (EPS) estimates for shares of Vaxart in a report released on Monday, November 18th. B. Riley analyst M. Mamtani now expects that the biotechnology company will post earnings of ($0.40) per share for the year, up from their previous forecast of ($0.54). The consensus estimate for Vaxart's current full-year earnings is ($0.43) per share. B. Riley also issued estimates for Vaxart's Q4 2024 earnings at ($0.11) EPS, Q1 2025 earnings at ($0.09) EPS, Q2 2025 earnings at ($0.10) EPS, Q3 2025 earnings at ($0.07) EPS, Q4 2025 earnings at ($0.08) EPS, FY2025 earnings at ($0.27) EPS and FY2026 earnings at ($0.28) EPS.

Separately, Oppenheimer started coverage on Vaxart in a research note on Thursday, August 15th. They issued an "outperform" rating and a $4.00 target price on the stock.

Vaxart Stock Performance

VXRT stock traded down $0.01 on Thursday, reaching $0.60. The company had a trading volume of 1,380,867 shares, compared to its average volume of 2,484,567. Vaxart has a 1 year low of $0.52 and a 1 year high of $1.54. The company's fifty day moving average is $0.78 and its 200 day moving average is $0.77. The company has a market cap of $106.33 million, a P/E ratio of -1.46 and a beta of 0.70.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Mesirow Financial Investment Management Inc. raised its position in Vaxart by 100.0% in the third quarter. Mesirow Financial Investment Management Inc. now owns 40,000 shares of the biotechnology company's stock valued at $34,000 after purchasing an additional 20,000 shares during the period. Tidal Investments LLC purchased a new stake in shares of Vaxart during the first quarter worth about $56,000. Sequoia Financial Advisors LLC purchased a new stake in shares of Vaxart during the second quarter worth about $65,000. XTX Topco Ltd increased its position in shares of Vaxart by 869.3% during the third quarter. XTX Topco Ltd now owns 136,466 shares of the biotechnology company's stock worth $116,000 after acquiring an additional 122,387 shares during the last quarter. Finally, Geode Capital Management LLC increased its position in shares of Vaxart by 15.8% during the third quarter. Geode Capital Management LLC now owns 2,543,228 shares of the biotechnology company's stock worth $2,160,000 after acquiring an additional 346,725 shares during the last quarter. Hedge funds and other institutional investors own 18.05% of the company's stock.

Vaxart Company Profile

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.